Description of Collaborative Activity: |
An every other month meeting to enhance communication between NCI and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies. |
